Borderline Resectable Pancreatic Ductal Adenocarcinoma Clinical Trials

11 clinical trials for Borderline Resectable Pancreatic Ductal Adenocarcinoma across international registries, including 6 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Gemcitabine, Cisplatin and Nab-Paclitaxel as Neoadjuvant Treatment for Patients With Resectable or Borderline Resectable Pancreatic Cancer — RECRUITING · PHASE2
• NALIRIFOX Before Surgery for the Treatment of Borderline Resectable Pancreatic Ductal Adenocarcinoma, Nectar Trial — RECRUITING · PHASE2
• Targeted Pathway Inhibition in Patients With Pancreatic Cancer — RECRUITING · PHASE1
• Using Tumour DNA and Proteins to Better Understand How Pancreatic Cancer Responds to Treatment — RECRUITING · NA
• PULSAR in Systemic Therapy for Pancreatic Cancer — RECRUITING · PHASE2
• Determining the Link Between Dietary Patterns, Fecal Microbiome and Response to Neoadjuvant Chemotherapy — RECRUITING
• SMAD4 Tailored Neoadjuvant Therapy for the Treatment of Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma, SMART-PANC Trial — NOT_YET_RECRUITING · PHASE2
• Samuraciclib for the Treatment of Patients With Resectable, Borderline Resectable, or Locally Advanced Basal Pancreatic Cancer — NOT_YET_RECRUITING · PHASE1
• DCE-MRI for Neoadjuvant Treatment Assessment in Patients With Borderline Resectable Pancreatic Cancer — NOT_YET_RECRUITING · PHASE1
• Personalize (Signature Driven) Neoadjuvant Chemotherapy Trial for Patients With Resectable Borderline Pancreatic Ductal Adenocarcinoma. — NOT_YET_RECRUITING · PHASE2
• AB801 in Combination With Chemotherapy and Immunotherapy for the Treatment of Patients With Borderline Resectable, Locally Advanced or Metastatic Cholangiocarcinoma or Pancreatic Cancer — NOT_YET_RECRUITING · PHASE1

Refine this search